Bausch Health Companies Inc.

NYSE:BHC

Drug Manufacturers - Specialty & Generic

Healthcare
$8.73 -2.21%

-$0.11 today

Market cap
$3.27B
Beta
0.41
P/E (TTM)
-1.5
EPS (TTM)
-$3.19
52W Low $4.57High $8.69

Volume 6.83M

Average 1.70M

BHC EBITDA Margin

EBITDA as a percentage of revenue.

Bausch Health Companies Inc.NYSE: BHC

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin holds steady near 35.9%

EBITDA Margin was 35.9% in Q2 FY2026, down 0.1 pp from a year earlier. On a trailing-twelve-month basis it was 18.9%, down 14.3 pp year over year. Over 3 fiscal years it narrowed by 4.5 pp.

Context

  • EBITDA Margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 48.8% for the fiscal year ending Dec 2026, up from 31.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
35.9%+62.0 pp QoQ
Last fiscal yearDec 2025
31.0%-1.6 pp YoY
LTMJun 2026
18.9%-14.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.1 pp+16.2 pp+16.3 pp
1 year-1.6 pp+17.8 pp+19.4 pp
3 years-4.5 pp+9.8 pp+14.3 pp
5 years+8.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
31.0%
Year-over-year change
-1.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How BHC compares with its peers on the latest reported figures

  • BHC's LTM Jun 2026 EBITDA Margin of 18.9% is the 5th highest of the 10 companies compared; the peer median is 9.3%.
  • Its year-over-year change of -14.3 pp is the 8th highest of 10, against a peer median of +1.3 pp.
  • Over three fiscal years its change of -4.5 pp compares with a peer median of +15.5 pp.
BHC Competitors Peer median
EBITDA Margin for BHC and competitors
Company Period LTM level YoY 3-year change
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 202656.1% +0.7 pp+5.1 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 202625.4% +15.5 pp+15.5 pp
CONConcentra Group Holdings Parent, Inc.LTM Sep 202620.5% +1.3 pp-0.2 pp
HAEHaemonetics CorporationLTM Jun 202619.3% -8.7 pp-2.2 pp
BHCBausch Health Companies Inc.LTM Jun 202618.9% -14.3 pp-4.5 pp
ALVOAlvotechLTM Mar 20269.3% -14.4 pp+584.9 pp
HCMHUTCHMED (China) LimitedLTM Jun 2025-1.2% +16.8 pp+86.5 pp
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026-3.5% +10.1 pp+15.6 pp
PRGOPerrigo Company plcLTM Jun 2026-25.2% -39.4 pp-26.7 pp
BEAMBeam Therapeutics Inc.LTM Jun 2026-40.5% +584.3 pp+435.7 pp
MLYSMineralys Therapeutics, Inc.FY2025— ——
Peer median (excluding BHC) 9.3%+1.3 pp+15.5 pp

Competitors are the stored peer set for BHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue8.43B8.12B8.76B9.63B10.27B
Cost of Revenue2.39B2.36B2.56B2.78B3.01B
Gross Profit6.04B5.76B6.2B6.84B7.25B
Gross Margin71.6%70.9%70.8%71.1%70.7%
Research & Development473M530M604M634M629M
Selling, General & Admin2.49B2.53B2.9B3.28B3.44B
Operating Expenses5.59B5.31B5.24B5.3B5.07B
Depreciation & Amortization1.55B1.39B1.26B1.27B1.21B
EBITDA3.26B2.88B2.89B3.13B3.18B
EBITDA Margin38.7%35.4%32.9%32.6%31.0%
Operating Income450M454M963M1.55B2.19B
Operating Margin5.3%5.6%11.0%16.1%21.3%
Interest Income7M14M26M33M48M
Interest Expense1.43B1.46B1.33B1.39B1.6B
Other Income / Expenses(1.47B)(583M)(1.35B)(1.38B)(1.82B)
Income Before Tax(1.02B)(129M)(390M)167M367M
Pre-Tax Margin-12.1%-1.6%-4.5%1.7%3.6%
Income Tax Expense(87M)83M221M239M247M
Net Income(948M)(225M)(592M)(46M)157M
Net Margin-11.2%-2.8%-6.8%-0.5%1.5%
EPS (Basic)(2.61)(0.62)(1.62)(0.13)0.43
EPS (Diluted)(2.61)(0.62)(1.62)(0.13)0.43
Weighted Avg Shares358.9M362M364.9M368M370.9M
Weighted Avg Shares (Diluted)358.9M362M364.9M368M375M

Bausch Health Companies Inc.

NYSE:BHC

Intrinsic Alpha fair value

Locked

Current Price

$8.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.